Skip to content

    Multiple Sclerosis Health Center

    Font Size

    Cancer Drug Rituxan Cuts MS Flare-ups

    Studies Show Multiple Sclerosis Patients Taking Rituxan Have Fewer Brain Lesions

    Fewer Flare-ups in People on Rituxan continued...

    Over the next six months, 58% fewer people taking the drug had their symptoms flare up than those taking placebo: 14.5% of those on Rituxan experienced at least one relapse compared with 34.3% of those receiving a placebo.

    Also, those on Rituxan had 91% fewer brain lesions seen on MRIs than those on placebo, Hauser says.

    The second study, designed to look at the safety of the drug, showed "no unexpected problems," says researcher Amit Bar-Or, MD, of the Montreal Neurological Institute at McGill University in Montreal.

    Twenty-six of 28 people were able to complete the 48-week study, in which they received two infusions of Rituxan two weeks apart and then another course six months later.

    Most side effects were limited to mild to moderate reactions to the drug infusion, such as headaches and chills, Bar-Or tells WebMD. The two people who dropped out had infusion-related headaches.

    Both studies were supported by Genentech Inc., and Biogen Idec., the companies that market the drug for certain types of lymphoma and for a moderate to severe form of rheumatoid arthritis in the U.S.

    Safety a Concern

    Gary Birnbaum, MD, director of the Multiple Sclerosis Treatment and Research Center in Golden Valley, Minn., says a big worry is a rare but rapidly fatal viral infection known as progressive multifocal leukoencephalopathy, or PML.

    And while people on Rituxan appear to have fewer MS flare-ups, "we still don't know if it will actually stop disease progression," Birnbaum tells WebMD.

    "These are important observations," Birnbaum says. "But we need longer trials to assess safety and effectiveness."

    Immediate Drug Therapy Better Than Waiting

    In a third study presented at the meeting, researchers reported that people who immediately start taking Betaseronat the first signs of MS are 41% less likely to have another attack over the next three years than those who delay treatment until they are diagnosed, as is currently done.

    Betaseron is a brand of the interferon beta medications that are already used to treat people with relapsing-remitting MS. Other brands of interferon beta, which may reduce the frequency of relapses and delay disability, are Avonex and Rebif.

    Today on WebMD

    nerve damage
    Learn how this disease affects the nervous system.
    woman applying lotion
    Ideas on how to boost your mood and self-esteem.
    woman pondering
    Get personalized treatment options.
    man with hand over eye
    Be on the lookout for these symptoms.
    brain scan
    worried woman
    neural fiber
    white blood cells
    sunlight in hands
    marijuana plant
    muscle spasm